| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
MBM-55S targets NIMA-related kinase 2 (Nek2), a serine/threonine kinase that plays a critical role in cell cycle regulation, particularly in centrosome duplication and spindle assembly. Nek2 is often overexpressed in cancer cells, making it a promising target for cancer therapy. By inhibiting Nek2, MBM-55S induces cell cycle arrest and apoptosis. The compound also shows activity against RSK1 (IC50 = 5.4 nM) and DYRK1a (IC50 = 6.5 nM), though it is more selective for Nek2.
|
|---|---|
| ln Vitro |
MBM-55S possesses IC50 values of 0.53, 0.84, and 7.13 μM that respectively suppress the growth of MGC-803, HCT-116, and Bel-7402 cells [1]. In HCT-116 cells, MBM-55S (0.5–1 μM; 24 hours) causes G2/M phase arrest and an accumulation of >4N content [1]. In HCT-116 cells, MBM-55S (0.5–1 μM; 24 hours) causes apoptosis in a concentration-dependent way [1].
MBM-55S exhibits potent in vitro activity as a Nek2 inhibitor. It has an IC50 of 1 nM for Nek2. The compound shows a 20-fold or greater selectivity in most kinases. MBM-55S effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. These in vitro activities confirm its potential as an anticancer agent. |
| ln Vivo |
In nude mice with HCT-116 xenografts, MBM-55S (20 mg/kg; i.p.; twice daily for 21 days) showed promising anticancer efficacy and a well-tolerated dosage regimen [1]. CL, Vss, T1/2, AUC0-t, and AUC0-∞ values of 33.3 mL/min/kg, 2.53 L/kg, 1.72 hours, 495 ng/h/mL, and 507 ng/h/mL, respectively, were observed after MBM-55S (1.0 mg/kg; iv) therapy [1].
MBM-55S has demonstrated in vivo activity in animal models. In nude mice bearing HCT-116 xenografts, MBM-55S (20 mg/kg; i.p.; twice a day for 21 days) exhibits good antitumor activity and a well-tolerated dose schedule. The compound shows no obvious toxicity to mice. These in vivo studies support the potential of MBM-55S as a therapeutic agent for cancer. |
| Enzyme Assay |
In vitro enzyme assays for MBM-55S involve measuring its inhibition of Nek2 kinase activity. These assays typically use recombinant Nek2 and a peptide substrate. The kinase is incubated with ATP and the substrate in the presence of varying concentrations of MBM-55S. The phosphorylation of the substrate is measured to determine the IC50 (1 nM). Selectivity is assessed by testing the compound against a panel of kinases. These assays confirm the compound’s mechanism as a potent and selective Nek2 inhibitor.
|
| Cell Assay |
Cell cycle analysis[1]
Cell Types: HCT-116 Cell Tested Concentrations: 0.5, 1 μM Incubation Duration: 24 hrs (hours) Experimental Results: Induced G2/M phase arrest and cells accumulating >4N content. Apoptosis analysis [1] Cell Types: HCT-116 Cell Tested Concentrations: 0.5, 1 μM Incubation Duration: 24 hrs (hours) Experimental Results: Cell apoptosis was induced in a concentration-dependent manner. In vitro cellular assays for MBM-55S are conducted in cancer cell lines such as HCT-116. Cells are treated with the compound at various concentrations, and cell cycle arrest and apoptosis are assessed by flow cytometry. Cell proliferation is measured using MTT or CellTiter-Glo assays. These assays characterize the compound’s anticancer activity. |
| Animal Protocol |
Animal/Disease Models: Male SD rat[1]
Doses: 1.0 mg/kg Route of Administration: intravenous (iv) (iv)injection (pharmacokinetic/PK/PK analysis) Experimental Results: CL, Vss, T1/2, AUC0-t, AUC0-∞ values are 33.3 mL /min/kg, 2.53 L/kg, 1.72 hrs (hrs (hours)), 495 ng/h/mL and 507 ml/min/kg. In vivo animal experiments with MBM-55S are conducted in mouse xenograft models of cancer, such as HCT-116 xenografts. Immunodeficient mice are engrafted with cancer cells, and MBM-55S is administered via intraperitoneal injection at doses such as 20 mg/kg, twice daily for 21 days. Tumor growth is measured over time, and tumor tissues are harvested for analysis of cell cycle and apoptosis markers. These studies evaluate the compound’s efficacy and safety in vivo. |
| ADME/Pharmacokinetics |
Pharmacokinetic data for MBM-55S are limited. The compound has a molecular weight of 734.73 and is soluble in DMSO. Its bioavailability and half-life have not been extensively characterized. The compound is typically stored at -20°C. Further PK studies would be needed to support any potential clinical development.
|
| Toxicity/Toxicokinetics |
MBM-55S has been evaluated for safety in preclinical studies. The compound shows no obvious toxicity to mice at therapeutic doses. The compound is intended for research use and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound. Further toxicity studies would be required to support any potential clinical development.
|
| References | |
| Additional Infomation |
MBM-55S is a potent Nek2 inhibitor with an IC50 of 1 nM. It shows a 20-fold or greater selectivity in most kinases. The compound induces cell cycle arrest and apoptosis and has anti-tumor activity with no obvious toxicity to mice. MBM-55S has demonstrated efficacy in HCT-116 xenograft models. It is available in high purity (95%) for research applications. Its potent Nek2 inhibition makes it a valuable tool for cancer research.
|
| Molecular Formula |
C36H39FN6O10
|
|---|---|
| Molecular Weight |
734.73
|
| Exact Mass |
734.271
|
| CAS # |
2083624-07-9
|
| Related CAS # |
MBM-55;2083622-09-5
|
| PubChem CID |
137639660
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
53
|
| Complexity |
851
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN(C)CCN1C=C(C=N1)C2=CC3=NC=C(N3C=C2)C4=CC(=C(C=C4)C(=O)N)OCC5=CC(=CC=C5)F.C(CC(=O)O)C(=O)O.C(CC(=O)O)C(=O)O
|
| InChi Key |
AXYNDQVILOZBNY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C28H27FN6O2.2C4H6O4/c1-33(2)10-11-34-17-22(15-32-34)20-8-9-35-25(16-31-27(35)14-20)21-6-7-24(28(30)36)26(13-21)37-18-19-4-3-5-23(29)12-19;2*5-3(6)1-2-4(7)8/h3-9,12-17H,10-11,18H2,1-2H3,(H2,30,36);2*1-2H2,(H,5,6)(H,7,8)
|
| Chemical Name |
butanedioic acid;4-[7-[1-[2-(dimethylamino)ethyl]pyrazol-4-yl]imidazo[1,2-a]pyridin-3-yl]-2-[(3-fluorophenyl)methoxy]benzamide
|
| Synonyms |
MBM55S; MBM 55S
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3610 mL | 6.8052 mL | 13.6104 mL | |
| 5 mM | 0.2722 mL | 1.3610 mL | 2.7221 mL | |
| 10 mM | 0.1361 mL | 0.6805 mL | 1.3610 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
